Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
PTGX

PTGX - Protagonist Therapeutics Inc Stock Price, Fair Value and News

33.97USD+0.02 (+0.06%)Market Closed

Market Summary

PTGX
USD33.97+0.02
Market Closed
0.06%

PTGX Alerts

  • 2 major insider sales recently.
  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)

PTGX Stock Price

View Fullscreen

PTGX RSI Chart

PTGX Valuation

Market Cap

2.0B

Price/Earnings (Trailing)

12.29

Price/Sales (Trailing)

33.21

EV/EBITDA

-10.59

Price/Free Cashflow

-31.05

PTGX Price/Sales (Trailing)

PTGX Profitability

EBT Margin

-212.32%

Return on Equity

28.93%

Return on Assets

25.76%

Free Cashflow Yield

-3.22%

PTGX Fundamentals

PTGX Revenue

Revenue (TTM)

60.0M

Rev. Growth (Yr)

200%

Rev. Growth (Qtr)

50%

PTGX Earnings

Earnings (TTM)

162.1M

Earnings Growth (Yr)

714.8%

Earnings Growth (Qtr)

658.51%

Breaking Down PTGX Revenue

Last 7 days

-0.2%

Last 30 days

15.9%

Last 90 days

19.8%

Trailing 12 Months

16.7%

How does PTGX drawdown profile look like?

PTGX Financial Health

Current Ratio

15.72

PTGX Investor Care

Shares Dilution (1Y)

2.45%

Diluted EPS (TTM)

2.53

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
202343.3M0060.0M
202246.9M45.5M35.2M26.6M
202131.2M27.2M24.4M27.4M
202020.0M22.8M25.7M28.6M
201921.7M014.2M17.1M
201831.3M42.5M39.9M30.9M
201700020.1M

Tracking the Latest Insider Buys and Sells of Protagonist Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 07, 2024
waddill william d.
acquired
103,040
12.88
8,000
-
Jun 07, 2024
waddill william d.
sold
-280,000
35.00
-8,000
-
Jun 07, 2024
patel dinesh v ph d
sold
-1,231,650
35.19
-35,000
president and ceo
Apr 18, 2024
ali asif
sold
-30,985
25.11
-1,234
chief financial officer
Apr 01, 2024
patel dinesh v ph d
sold
-707,750
28.31
-25,000
president and ceo
Mar 07, 2024
selick harold e
acquired
12,266
1.89
6,490
-
Mar 01, 2024
waddill william d.
sold
-406,636
31.34
-12,975
-
Mar 01, 2024
patel dinesh v ph d
sold
-948,600
31.62
-30,000
president and ceo
Mar 01, 2024
waddill william d.
acquired
79,017
6.09
12,975
-
Mar 01, 2024
ali asif
sold
-459,318
32.2374
-14,248
chief financial officer

1–10 of 50

Which funds bought or sold PTGX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 04, 2024
DekaBank Deutsche Girozentrale
unchanged
-
135,000
461,000
-%
May 29, 2024
Opaleye Management Inc.
unchanged
-
676,200
3,260,410
0.71%
May 24, 2024
FARALLON CAPITAL MANAGEMENT LLC
added
0.08
34,538,000
166,028,000
0.75%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
67.67
170,785
323,785
0.04%
May 17, 2024
Ikarian Capital, LLC
sold off
-100
-7,314,670
-
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-6.26
211,135
1,366,620
-%
May 16, 2024
COMERICA BANK
added
18.94
2,617
7,822
-%
May 16, 2024
JANE STREET GROUP, LLC
added
11.43
678,834
2,351,140
-%
May 15, 2024
SUVRETTA CAPITAL MANAGEMENT, LLC
new
-
882,365
882,365
0.03%
May 15, 2024
Voya Investment Management LLC
added
60.58
1,017,380
2,008,990
-%

1–10 of 47

Are Funds Buying or Selling PTGX?

Are funds buying PTGX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own PTGX
No. of Funds

Unveiling Protagonist Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
citadel advisors llc
0.0%
6
SC 13G/A
Feb 14, 2024
biotechnology value fund l p
5.4%
3,120,957
SC 13G/A
Feb 14, 2024
rtw investments, lp
9.2%
5,315,514
SC 13G/A
Feb 14, 2024
point72 asset management, l.p.
4.5%
2,613,453
SC 13G/A
Feb 13, 2024
vanguard group inc
5.47%
3,153,916
SC 13G/A
Feb 07, 2024
adage capital partners gp, l.l.c.
2.24%
1,291,701
SC 13G/A
Feb 02, 2024
farallon capital partners, l.p.
0.7%
386,653
SC 13G/A
Jan 24, 2024
blackrock inc.
9.6%
5,543,902
SC 13G/A
Jan 23, 2024
state street corp
4.73%
2,729,929
SC 13G/A
Dec 18, 2023
point72 asset management, l.p.
5.5%
3,186,077
SC 13G

Recent SEC filings of Protagonist Therapeutics Inc

View All Filings
Date Filed Form Type Document
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 07, 2024
144
Notice of Insider Sale Intent
Jun 07, 2024
144
Notice of Insider Sale Intent
May 07, 2024
8-K
Current Report
May 07, 2024
10-Q
Quarterly Report
Apr 26, 2024
DEFA14A
DEFA14A
Apr 26, 2024
DEF 14A
DEF 14A
Apr 26, 2024
ARS
ARS
Apr 19, 2024
4
Insider Trading

Peers (Alternatives to Protagonist Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
56.6B
6.8B
17.55% 15.42%
-9.49
8.27
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.1B
2.0B
6.10% -19.49%
-60.58
10.04
75.20% 68.82%
16.1B
2.5B
5.03% -10.77%
78.14
6.5
13.74% 186.89%
13.5B
3.8B
4.06% -3.24%
18.05
3.57
8.58% 129.81%
MID-CAP
5.4B
107.9M
0.63% 71.22%
-9.82
48.09
54.84% -28.31%
5.2B
524.1M
-1.19% -54.45%
-12.36
9.84
394.93% 39.61%
3.4B
251.0M
-5.41% -4.45%
-11.47
13.54
73.58% -86.73%
3.2B
240.7M
16.82% -26.89%
-6.77
12.77
-1.03% -213.92%
2.5B
813.8M
1.25% -38.59%
-1.5K
3.12
56.43% 98.83%
2.2B
996.6M
20.98% 97.26%
-5.59
2.23
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-4.75% 32.39%
28.02
4.44
60.38% -34.49%
547.7M
881.7K
19.55% 492.49%
-16.22
481.06
-77.61% 33.36%
245.6M
4.2M
-16.55% 51.92%
-1.97
59.05
-66.30% 48.24%
22.0M
2.1M
40.11% 239.32%
-0.95
7.61
-13.45% 69.54%

Protagonist Therapeutics Inc News

Latest updates
MarketBeat5 hours ago

Protagonist Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q12018Q42018Q32018Q2
Revenue50.0%254,953,000169,968,66784,984,333--859,00025,722,0008,617,00010,286,0002,265,0006,189,0005,650,00013,114,0006,217,0003,647,0003,894,0004,141,0001,560,0002,353,0006,117,00011,674,000
Operating Expenses31.6%48,644,00036,951,00036,021,00036,516,00032,303,00042,302,00046,833,00045,633,00044,212,00033,147,00030,210,00024,480,00020,886,00024,434,00023,344,00020,018,00021,308,00016,208,00017,765,00015,506,00020,913,000
  S&GA Expenses85.2%14,910,0008,052,0008,605,0006,632,0006,901,0007,691,00010,515,0007,260,0007,256,0006,715,0005,965,0004,994,0004,891,0004,177,0004,576,0004,107,0004,015,0003,764,0003,516,5003,361,0003,178,000
  R&D Expenses16.7%33,734,00028,899,00027,416,00029,884,00025,402,00034,611,00036,318,00038,373,00036,956,00026,432,00024,245,00019,486,00015,995,00020,257,00018,768,00015,911,00017,293,00012,444,00014,248,50012,145,00017,735,000
EBITDA Margin0.0%-2.11-2.11-2.92-4.75-3.54-2.74-2.66-4.56-4.35-2.94-----------
Interest Expenses------------127,00019,000209,000243,000------
Income Taxes-3,300,000----------2,500-1,100,000200,000833,000-102,000183,000-799,000--
Earnings Before Taxes-210,666,000--33,725,000-----36,907,000-33,804,000-30,842,000-23,998,000-18,886,000-7,763,000-18,292,000-19,904,000-16,644,500-16,511,000-13,920,000-14,664,000-8,735,000-8,663,000
EBT Margin0%-2.12-2.12-2.94-4.79-3.57-2.76-2.68-4.59-4.41-2.99-----------
Net Income658.5%207,340,00027,335,000-33,725,000-34,194,000-31,232,000-41,037,000-20,930,000-36,907,000-33,804,000-30,842,000-23,998,000-18,886,000-7,763,000-19,421,000-20,080,000-17,501,000-16,409,000-14,103,000-13,865,000-8,735,000-8,663,000
Net Income Margin305.3%2.70-1.32-3.24-4.79-3.70-2.92-2.61-4.59-4.41-2.99-----------
Free Cashflow-263.3%-27,671,00016,941,000-34,357,000-31,705,000-25,363,000-13,925,000-37,939,000-27,135,000-28,735,000-24,200,000-----------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets75.8%629358330320240248282311348348373404298324217225135155155148132
  Current Assets76.5%628356325317236243277304342341328372286316204217126145144137123
    Cash Equivalents-7.6%17318723123512812615312098.0012412119283.0011884.0014660.0033.0050.0071.0070.00
  Net PPE-7.0%1.001.001.001.001.002.002.002.002.002.002.002.001.001.001.002.002.002.002.002.002.00
Liabilities223.5%69.0021.0028.0026.0024.0032.0039.0043.0047.0048.0044.0047.0039.0045.0048.0057.0072.0075.0059.0064.0031.00
  Current Liabilities87.6%40.0021.0028.0026.0023.0031.0037.0040.0043.0044.0039.0043.0035.0040.0039.0035.0036.0035.0031.0033.0024.00
  Long Term Debt-----------------10.0010.00---
Shareholder's Equity66.5%56033730229421621624426830230033035725928017016763.0080.0095.0084.00101
  Retained Earnings33.7%-408-615-643-608-570-536-502-471-430-409-372-338-307-283-264-257-237-217-200-183-154
  Additional Paid-In Capital1.7%969952945903787753747740733710702696567563435425300298296268256
Shares Outstanding1.5%59.0058.0058.0057.0051.0049.0049.0049.0049.0046.0048.0045.00---------
Float----1,600---379,500---2,100---641---212-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-261.7%-27,42916,960-26,611-26,238-34,347-31,635-25,201-13,635-37,666-26,939-28,470-23,700-28,756-18,867-16,287-21,482-15,848-14,289-14,2463,670-16,662
  Share Based Compensation41.7%9,3526,6016,7658,3437,5845,5125,9506,8055,9355,0244,7753,9362,6601,9671,8881,9962,0482,1602,2012,0131,979
Cashflow From Investing109.9%6,071-61,287-13,55925,7629,8263,93557,27534,734-4,47627,867-44,7077,773-6,793-74,402-54,122-5,17142,730-12,554-32,039-13,2254,108
Cashflow From Financing1266.0%7,19952735,315108,17226,46355368068016,9252,1731,381125,390979126,9817,669112,5773999,77925,23710,630390
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

PTGX Income Statement

2024-03-31
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Consolidated Statements of Operations  
License and collaboration revenue$ 254,953$ 0
Revenue from Contract with Customer, Product and Service [Extensible List]License and Collaboration AgreementLicense and Collaboration Agreement
Operating expenses:  
Research and development$ 33,734$ 27,416
General and administrative14,9108,605
Total operating expenses48,64436,021
Income (loss) from operations206,309(36,021)
Interest income4,3762,491
Other expense, net(19)(195)
Income (loss) before income tax expense210,666(33,725)
Income tax expense(3,326)0
Net income (loss)$ 207,340$ (33,725)
Net income (loss) per share, basic$ 3.41$ (0.67)
Net income (loss) per share, diluted$ 3.26$ (0.67)
Weighted-average shares used to compute net income (loss) per share, basic60,855,68950,573,650
Weighted-average shares used to compute net income (loss) per share, diluted63,595,32850,573,650

PTGX Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 172,568$ 186,727
Marketable securities150,067154,890
Receivable from collaboration partner300,04310,000
Prepaid expenses and other current assets4,8753,960
Total current assets627,553355,577
Property and equipment, net1,1111,195
Restricted cash - noncurrent225225
Operating lease right-of-use asset387954
Total assets629,276357,951
Current liabilities:  
Accounts payable3,507772
Payable to collaboration partner33
Accrued expenses and other payables16,48719,358
Deferred revenue - current16,125 
Income taxes payable3,326 
Operating lease liability - current4621,141
Total current liabilities39,91021,274
Deferred revenue, noncurrent28,922 
Total liabilities68,83221,274
Commitments and contingencies
Stockholders' equity:  
Preferred stock, $0.00001 par value, 10,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.00001 par value, 90,000,000 shares authorized; 58,600,787 and 57,708,613 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively11
Additional paid-in capital969,042952,491
Accumulated other comprehensive loss(229)(105)
Accumulated deficit(408,370)(615,710)
Total stockholders' equity560,444336,677
Total liabilities and stockholders' equity$ 629,276$ 357,951
PTGX
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of erythrocytosis, iron overload, and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that is in Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist, which is in Phase II clinical trials for inflammatory bowel disease. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
 CEO
 WEBSITEprotagonist-inc.com
 INDUSTRYBiotechnology
 EMPLOYEES106

Protagonist Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Protagonist Therapeutics Inc? What does PTGX stand for in stocks?

PTGX is the stock ticker symbol of Protagonist Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Protagonist Therapeutics Inc (PTGX)?

As of Wed Jun 12 2024, market cap of Protagonist Therapeutics Inc is 1.99 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PTGX stock?

You can check PTGX's fair value in chart for subscribers.

What is the fair value of PTGX stock?

You can check PTGX's fair value in chart for subscribers. The fair value of Protagonist Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Protagonist Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PTGX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Protagonist Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether PTGX is over valued or under valued. Whether Protagonist Therapeutics Inc is cheap or expensive depends on the assumptions which impact Protagonist Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PTGX.

What is Protagonist Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Jun 12 2024, PTGX's PE ratio (Price to Earnings) is 12.29 and Price to Sales (PS) ratio is 33.21. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PTGX PE ratio will change depending on the future growth rate expectations of investors.